ES2080307T3 - Composiciones farmaceuticas. - Google Patents

Composiciones farmaceuticas.

Info

Publication number
ES2080307T3
ES2080307T3 ES91906832T ES91906832T ES2080307T3 ES 2080307 T3 ES2080307 T3 ES 2080307T3 ES 91906832 T ES91906832 T ES 91906832T ES 91906832 T ES91906832 T ES 91906832T ES 2080307 T3 ES2080307 T3 ES 2080307T3
Authority
ES
Spain
Prior art keywords
pharmaceutical compositions
tnf
taurultam
taurolidine
sequential
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91906832T
Other languages
English (en)
Inventor
Rolf Wilhelm Pfirrmann
Peter Geistlich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ed Geistlich Soehne AG fuer Chemische Industrie
Original Assignee
Ed Geistlich Soehne AG fuer Chemische Industrie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ed Geistlich Soehne AG fuer Chemische Industrie filed Critical Ed Geistlich Soehne AG fuer Chemische Industrie
Application granted granted Critical
Publication of ES2080307T3 publication Critical patent/ES2080307T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

LA INVENCION SUMINISTRA PRODUCTOS QUE CONTIENEN EL FACTOR DE LA NECROSIS TUMORAL (TNF) Y TAUROLIDINA Y / O TAURULTAM COMO UNA PREPARACION COMBINADA PARA EL USO SIMULTANEO TANTO SEPARADO COMO SECUENCIAL EN PACIENTES QUE SUFREN DE CONDICIONES MEDICAS TRATADAS CON TNF.
ES91906832T 1990-03-15 1991-03-15 Composiciones farmaceuticas. Expired - Lifetime ES2080307T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909005856A GB9005856D0 (en) 1990-03-15 1990-03-15 Compositions

Publications (1)

Publication Number Publication Date
ES2080307T3 true ES2080307T3 (es) 1996-02-01

Family

ID=10672686

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91906832T Expired - Lifetime ES2080307T3 (es) 1990-03-15 1991-03-15 Composiciones farmaceuticas.

Country Status (8)

Country Link
US (1) US5593665A (es)
EP (1) EP0520021B1 (es)
JP (1) JPH05505615A (es)
CA (1) CA2078221C (es)
DE (1) DE69115263T2 (es)
ES (1) ES2080307T3 (es)
GB (1) GB9005856D0 (es)
WO (1) WO1991013628A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303596B1 (en) 1997-05-22 2001-10-16 Oklahoma Medical Research Foundation Use of taurolidine for treatment of leukemias
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US6479481B1 (en) 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
US20030027818A1 (en) 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
US8304390B2 (en) 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US6011030A (en) * 1997-09-22 2000-01-04 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating symptoms of microbial infection or sepsis
US5972933A (en) * 1998-01-08 1999-10-26 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating microbial infections
US6166007A (en) 1998-07-02 2000-12-26 Sodemann; Klaus Antimicrobial locks comprising taurinamide derivatives and carboxylic acids and/or salts thereof
US6117868A (en) * 1998-09-16 2000-09-12 Ed. Geistlich Sohne Ag Fur Chemische Industrie Treatment of gastrointestinal ulcers or gastritis caused by microbial infection
US8030301B2 (en) 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US7892530B2 (en) 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US7345039B2 (en) 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US6821968B2 (en) * 2001-09-26 2004-11-23 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Stable taurolidine electrolyte solutions
US20050096314A1 (en) * 2001-04-03 2005-05-05 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US20030225067A1 (en) * 1999-06-04 2003-12-04 Ruediger Stendel Microdialysis methods and applications for treatment and/or prophylaxis of tumors and/or infections in the central nervous system (CNS) and/or in other parenchymal organs
US6685694B2 (en) 1999-07-23 2004-02-03 Vasca, Inc. Methods and kits for locking and disinfecting implanted catheters
US6679870B1 (en) 1999-07-23 2004-01-20 Vasca, Inc. Methods and kits for locking and disinfecting implanted catheters
EP1246617B1 (en) 1999-12-06 2006-09-13 Rhode Island Hospital Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of ovarian cancer
CN100519525C (zh) * 1999-12-06 2009-07-29 葛兰素集团有限公司 芳香砜类及其医疗用途
US20020004502A1 (en) * 2000-01-05 2002-01-10 Redmond H. Paul Treatment of inflammatory bowel disease
AU779362B2 (en) * 2000-10-27 2005-01-20 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
EP1450814B1 (en) 2001-10-01 2016-11-30 Geistlich Pharma AG Methods of inhibiting metastases
JP5346148B2 (ja) * 2003-03-28 2013-11-20 エー・デー・ガイストリヒ・ゾーネ・アクチェンゲゼルシャフト・フュール・ヒェーミシェ・インダストリー 抗新生物性組成物および治療方法
US8236794B2 (en) 2003-09-29 2012-08-07 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of mesothelioma
US7696182B2 (en) 2004-11-02 2010-04-13 Nd Partners, Llc Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin
US8167847B2 (en) 2006-06-22 2012-05-01 Excelsior Medical Corporation Antiseptic cap and antiseptic cap equipped plunger and syringe barrel assembly
CA3010981C (en) * 2016-01-11 2024-09-17 Cormedix Inc. Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers
US11541061B2 (en) 2016-01-11 2023-01-03 Cormedix Inc. Neuroblastoma treatment with taurolidine hydrolysis products
US20190381060A1 (en) 2016-01-11 2019-12-19 Cormedix Inc. Taurolidine treatment for myc-expressing tumors in mammalian bodies
WO2020047530A1 (en) * 2018-08-31 2020-03-05 Cormedix Inc. Taurolidine treatment for myc-expressing tumors in mammalian bodies
US11738120B1 (en) 2022-04-14 2023-08-29 Cormedix Inc. Synthesis of taurolidine, purity profiles and polymorphs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8328111D0 (en) * 1983-10-20 1983-11-23 Geistlich Soehne Ag Chemical compounds
US5210083A (en) * 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
WO1988002632A1 (en) * 1986-10-16 1988-04-21 President And Fellows Of Harvard College Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases
US4980160A (en) * 1986-10-16 1990-12-25 Biogen, Inc. Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases

Also Published As

Publication number Publication date
EP0520021A1 (en) 1992-12-30
JPH05505615A (ja) 1993-08-19
CA2078221C (en) 2005-08-16
US5593665A (en) 1997-01-14
DE69115263T2 (de) 1996-08-08
GB9005856D0 (en) 1990-05-09
DE69115263D1 (de) 1996-01-18
EP0520021B1 (en) 1995-12-06
CA2078221A1 (en) 1991-09-16
WO1991013628A1 (en) 1991-09-19

Similar Documents

Publication Publication Date Title
MX9102110A (es) Muteina de factor de necrosis tumoral humano o una sal farmaceuticamente aceptable de la misma,procedimiento para su preparacion y composicion farmaceutica que la contiene
ES2057124T3 (es) Producto terapeutico para el tratamiento de estados peri- o post-menopausicos.
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
ES2156840T1 (es) Medicamento que contiene polisulfato de pentosano e implante para tratar la fibrosis.
ES2057439T3 (es) Uso de una composicion para la fabricacion de un medicamento para tratar los sintomas de excesos o abusos de comida y bebida.
DK1036058T3 (da) Adamantanderivater
DK1036059T3 (da) Adamantanderivater
AU6998791A (en) Use of n-myristoyl-(s)-phenylalanine for obtaining medicinal products intended for the treatment of diseases involving myristoylation
ES2190674T3 (es) Uso de n-alquil derivados de cadena larga de desoxinojirimicina para la fabricacion de un medicamento para el tratamiento de enfermedades de acumulacion de glucolipidos.
AR016798A1 (es) Uso de una cepa de lactobacillus para la elaboracion de un medicamento
DE69820108D1 (de) Doppelkapsel zur verabreichung von arzneimitteln für vielfache therapien
ES2034790T3 (es) Empleo de al menos una citroquina para la preparacion de un medicamento para el tratamiento sistematico de lesiones preneoplasticas.
BR0115162A (pt) Tratamentos antitumorais eficazes
CA2078221A1 (en) Pharmaceutical compositions comprising taurolidine and/or taurultam
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
HUP0100539A2 (hu) D-vitamint és kálciumot tartalmazó gyógyászati készítmények és eljárás azok előállítására
ES2193233T3 (es) Uso de amiodipina, una sal de la misma o felodipina en combinacion con un inhibidor ace en la fabricacion de un medicamento para el tratamiento de insuficiencia cardiaca conjuntiva no isquemica.
RU95106680A (ru) Бициклические ароматические соединения и содержащие их фармацевтические и косметические композиции
ES2038650T3 (es) Procedimiento para preparar una composicion farmaceutica que comprende 3'-desoxitimidin-2'-eno-(3'-desoxi-2',3'-dideshidrotimidina) para tratar pacientes infectados con retrovirus.
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
ES2185655T3 (es) Fracciones de acido aurintricarboxilico y analogos con actividad anti-angiogenica y metodos de uso.
ES2054718T3 (es) El uso de gepirona para la preparacion de una composicion farmaceutica para el tratamiento de la depresion atipica.
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.
MX9300558A (es) Nueva sulfonilurea, procedimiento para su preparacion y formulado farmaceutico que la contiene.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 520021

Country of ref document: ES